Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 20/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Finrozole SCHEMBL1649445 | 1.00 | CYP19A1 (0.62) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| Finrozole SCHEMBL1658815 | 1.00 | CYP19A1 (0.62) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL8104979 | 0.89 | CYP19A1 (0.72) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL6016102 | 0.84 | CYP19A1 (0.49) | CYP19A1 | |
| SCHEMBL5583460 | 0.80 | CYP19A1 (0.44) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL8408716 | 0.80 | CYP19A1 (0.62) | CYP19A1CYP3A4CYP11B1CYP11B2 | |
| SCHEMBL8104665 | 0.80 | CYP19A1 (0.52) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL13285157 | 0.78 | CYP19A1 (0.85) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL8095364 | 0.77 | CYP19A1 (0.59) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL8095377 | 0.77 | CYP19A1 (0.68) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541462-B2 | Tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors | AETERNA ZENTARIS GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20120122763-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
| US-8148546-B2 | Tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors | AETERNA ZENTARIS GMBH (DE) | 2012-04-03 | — | — | US | disclosed |
| US-20090170783-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| EP-1988098-A1 | Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors | AEterna Zentaris GmbH (DE) | 2008-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170783-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | GPR88, GPR34, GPR27 | CYP19A1 2708/4885CYP3A4 1753/4885CYP11B1 320/4885 |
| US-20120122763-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | GPR88, GPR34, GPR27 | CYP19A1 2708/4885CYP3A4 1753/4885CYP11B1 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.